Jinfiniti Precision Medicine Files IPO Prospectus: Pioneering NAD-Centric Aging Biomarker Testing and Personalized Longevity Solutions

NAD is an essential vitamin for life and a coenzyme required for the function of over 500 enzymes. As we age, NAD levels in the human body decline.

Most people begin to experience NAD+ deficiency in their 30s, which can lead to numerous conditions such as chronic fatigue, poor sleep, inflammation, arthritis, heart failure, infertility, and nearly all age-related diseases.

Fortunately, NAD levels can be elevated to the optimal range through NAD testing and supplementation with NAD precursors.

Jinfiniti Precision Medicine (hereinafter referred to as “Jinfiniti”) is a company dedicated to optimizing NAD levels. Founded in 2018 and headquartered in Augusta, Georgia, USA, Jinfiniti specializes in precision medicine research and has developed a series of innovative biomarker testing products to help clients monitor and improve their health status.

Jinfiniti’s anti-aging services encompass three main categories: biomarker testing, nutritional supplements, and healthy lifestyle coaching. These services help patients address aging- and disease-related issues driven by NAD+ and other micronutrient deficiencies, oxidative stress/DNA damage, glycation/blood glucose dysregulation, chronic inflammation, cellular senescence, and metabolic dysfunction.

Dr. She Jinxiong, Founder and CEO of Jinfiniti Precision Medicine, grew up in rural China in a poor family with illiterate parents. As a child, he witnessed his older sister pass away at the age of 36, and saw his father’s life threatened by severe liver fibrosis, which nearly claimed his life when Dr. She was just 12 years old. After graduating from university at the age of 20, he himself developed serious liver problems.

Witnessing his family suffer from poor health and premature aging, She Jinxiong developed a deeper reverence and sense of mission toward life and health. He dedicated himself to scientific research in the fields of health and longevity, and through relentless academic pursuit, rose from a mountain village to the global stage, where he has been invited to deliver speeches around the world."Has been researching cellular health and aging at a top-tier university for over 40 years.". On this long and inspiring journey of remarkable turnaround, Dr. She Jinxiong has achieved numerous outstanding accomplishments in the field of anti-aging.

From 1984 to 1987, Dr. She Jinxiong earned his Ph.D. in Molecular and Population Genetics from the University of Montpellier, France. From 1988 to 1990, he conducted postdoctoral research in the Department of Pathology at the University of Florida, USA.

In 2002, Dr. She was appointed as the Georgia Research Alliance Eminent Scholar in Genomic Medicine at the Medical College of Georgia. He is the Founding Director of the Center for Biotechnology and Genomic Medicine, a Professor in the Department of Obstetrics and Gynecology and the Department of Health Technology, and the Director of two core research facilities (Genomics, Proteomics, and Mass Spectrometry) at Augusta University.

Throughout his extensive academic career, he has published more than 400 peer-reviewed papers, achieved an H-index of 76, accumulated over 19,000 citations, and secured more than $100 million in research funding. Dr. She is also recognized as one of the “Top 20 Medical Researchers in Georgia” and has served as President of the American Chinese Geneticists Association and Chair of the Immunology, Transplantation, and Immunogenetics Committee of the American Diabetes Association.

Dr. She Jinxiong and his wife co-founded Jinfiniti, developing innovative medical tests and nutritional supplements, and helping users improve their health and combat aging through the “TAO” program.

Jinfiniti’s core philosophy, TAO, can be summarized by three keywords: Test, Act, and Optimize. TAO originates from the concept of “Yin and Yang” in ancient Chinese Taoist philosophy. Jinfiniti believes that this conceptual framework also applies to aging and life, where the Yin-Yang duality in life corresponds to DNA/genes (Yin, the dark) and environmental or non-genetic factors (Yang, the light).

The genes inherited from one’s parents constitute the primary code for health and longevity, typically remaining unchanged throughout life. However, gene activity or expression is influenced by numerous non-genetic, i.e., environmental factors, such as dietary habits, exercise routines, sleep patterns, stress levels, and exposure to pollution, radiation, ultraviolet light, toxins, infections, and other environmental risks. These environmental factors can significantly impact an individual’s health status and lifespan.

Jinfiniti believes that when the forces of Yin and Yang achieve perfect balance and harmony, cells and the body function optimally; therefore, this state should be maintained as much as possible. However, with advancing age, the balance and harmony between Yin and Yang become increasingly disrupted, leading to a growing prevalence of suboptimal health conditions and predisposing individuals to more severe diseases. Fortunately, this condition is reversible in its early stages.

In the realm of aging biomarker testing, Jinfiniti focuses on measuring NAD levels, positing that “achieving optimal NAD levels is the starting point for extending healthspan and enhancing vitality.”

This testing method collects samples via fingerstick blood and offers high detection accuracy, R²The assay achieved a value of 0.98, with an average coefficient of variation (CV) of 3.1% and high reproducibility. Jinfiniti Precision Medicine offers one of the few consumer-focused NAD testing services currently available. Through this testing, it is possible to assess whether patients have NAD deficiency, thereby identifying the most suitable products and optimal supplement dosages tailored to individual needs, along with providing actionable recommendations for NAD optimization.

If users have already taken NAD supplements or other products, testing can help determine whether the product is effective for them and assist in deciding whether to switch products or adjust the dosage to better optimize NAD levels. Jinfiniti emphasizes that there is significant variation in the efficacy of NAD supplement products on the market, many of which have not been tested in clinical studies. Most NAD products fail to achieve the expected results or cannot optimize NAD levels for most people; therefore, NAD testing is essential.

In the specific testing service, patients need to register on jinfiniti.com using the unique ID number included in the test kit, then collect a fingerstick blood sample and mail it back to Jinfiniti’s laboratory. Within 3–7 days, they can log in to the company’s secure website to view their reports and recommendations, with 100% privacy and data protection ensured throughout the process.

In addition to NAD level testing, Jinfiniti has developed other aging biomarker testing services, such as epigenetic age testing and the AgingSOS product series.

Specifically, Jinfiniti’s epigenetic age test, Agerate, employs the gold-standard DNA methylation analysis method to measure the methylation status of over 10,000 CpG sites. This clock was discovered and validated using data from more than 10,000 individuals and an AI-driven proprietary algorithm.

The AgingSOS product line comprises three tiers: the Basic, Advanced, and Personalized packages. The Basic AgingSOS Starter Panel measures 16 key, actionable biomarkers, enabling users to understand how to improve suboptimal health conditions and prevent age-related diseases. The Advanced AgingSOS Advanced Panel detects 22 biomarkers, including those in the Basic package, and assesses micronutrient status, cellular senescence, oxidative stress, inflammation, metabolism, tissue damage, DNA damage, and sirtuin activity. It is particularly suitable for individuals currently participating in or planning to embark on anti-aging regimens.

The AgingSOS Longevity Biomarkers personalized panel is designed to flexibly meet users’ needs for aging biomarker testing. Users can select from over 200 biomarkers offered by Jinfiniti to create their own customized AgingSOS biomarker panel. This panel is an ideal choice for clinics or research institutions with high-volume or specialized requirements.

Testing of AgingSOS biomarkers was conducted at Jinfiniti’s CLIA-certified laboratory. Most biomarkers were assayed using FDA- or CE-approved reagents, while others were measured using laboratory-developed tests (LDTs) that have been comprehensively validated for reproducibility.

Following the completion of testing, the Jinfiniti Health Index (W-Index) and various biomarkers can help users gain insights into their overall health status, future health risks, the efficacy of anti-aging interventions, and actionable data for extending lifespan and improving existing health conditions.

In addition, the company has developed Accuri Vitality Boost, an NAD-optimizing supplement, for which a patented formulation is currently pending.

Clinically validated, this formula comprises NAD precursors, creatine monohydrate, D-ribose, and nicotinamide. In addition to providing essential support individually, these ingredients exert synergistic effects, thereby more effectively elevating NAD levels and revitalizing cellular and systemic vitality compared to other NAD products. Furthermore, all ingredients in this supplement have been tested by third-party laboratories, demonstrating high purity, with certificates of analysis available upon request.

Accuri Vitality Boost powers multiple pathways for cellular NAD production, including one-step NAD precursors and the salvage pathway that recycles nicotinamide into NAD.

Among these, D-ribose is a key component of NAD and can further enhance the efficiency of NAD synthesis via the salvage pathway. Creatine monohydrate promotes muscle growth and is therefore widely used in the fitness industry. However, it is less well known that creatine also acts as an “ATP battery”: it stores energy when ATP is abundant and releases it to provide energy for muscles and cells when additional cellular energy is required.

Before and after 3–4 weeks of supplement use, Jinfiniti will evaluate the product’s efficacy for users and determine the appropriate dosage through its intracellular NAD+ testing. If a user takes Accuri Vitality Boost as recommended in terms of timing and dosage, but their NAD+ levels do not reach the optimal range identified by the company’s intracellular NAD+ test, Jinfiniti will work with the user to develop a personalized solution to achieve optimal NAD+ levels; otherwise, the company will issue a refund, backed by a 60-day money-back guarantee.

According to the company, Accuri Vitality Boost can improve sleep quality, reduce inflammation and muscle and joint pain, alleviate allergy and asthma symptoms, enhance mental clarity and mitigate dementia symptoms, and improve the function of multiple organs, including the liver, kidneys, heart, and thyroid. Jinfiniti’s supplements are manufactured in GMP-certified facilities to ensure quality, safety, and consistency.

In a study evaluating the efficacy of Accuri Vitality Boost in optimizing intracellular NAD levels, 26 volunteers aged 35–65 years were administered a daily supplement of 2,000 mg of Accuri Vitality Boost. The results demonstrated that after four weeks, 22 out of the 26 participants (85%) achieved optimal NAD levels. Two additional participants reached near-optimal levels, which could be further optimized with a slight increase in dosage. On average, NAD levels increased by 100%.

In addition to supplements, Jinfiniti also provides patients with healthy lifestyle coaching, including balanced nutrition, daily exercise, sleep, stress reduction, toxin avoidance, and injury prevention.

Currently, Jinfiniti’s products are used and recommended to patients by over 2,000 physicians, and have been adopted and endorsed by Olympic athletes, NFL players, and other elite athletes. Furthermore, the company was listed among the Top 20 Most Innovative Companies in Business Worldwide Magazine’s 2021 ranking.

In recent years, the anti-aging sector has emerged as a highly prominent field of interest. However, compared to various anti-aging interventions such as exercise and wellness, skin wrinkle reduction, and dietary supplementation, aging assessment has clearly not received sufficient attention, with only a handful of companies in China entering this niche market. Encouragingly, the academic community has already achieved certain breakthroughs in scientific research within this field.

On July 19, 2023, the China Aging Biomarker Consortium was invited to publish a Correspondence article titled “The Aging Biomarker Consortium represents a new era for aging research in China” in Nature Medicine, contributing Chinese paradigms and insights to the field of anti-aging.

On July 28, 2023, multiple research groups from the Aging Biomarker Consortium (ABC) in China collaborated closely to publish a research paper titled “Determining a Multimodal Aging Clock in a Cohort of Chinese Women” in the journal Med. This study systematically mapped, for the first time, a navigational atlas of aging biomarkers across five dimensions in Chinese women, established a multi-level composite aging clock for this population, and leveraged this clock to elucidate the dynamic patterns of aging in Chinese women as well as the potential interventional effects of hormone replacement therapy on female aging. The study establishes a new paradigm for systems biology research on the quantification of population aging, providing a solid foundation for the development and clinical application of aging clocks.

In the field of aging, prevention should take precedence over treatment. To effectively combat aging, the focus lies in the early detection and resolution of issues, rather than intervening only after age-related health problems have become severe. This underscores the value of testing for biological markers of aging. Currently, most related companies both in China and abroad are still in the clinical research stage. However, with the accumulation of scientific achievements, increased capital attention, and the involvement of top-tier scientists, we are confident in anticipating their commercial realization and the eventual fulfillment of the vision to help people truly “extend their healthspan and lifespan.”